Brief: Tiziana Announces Reduction Of Side Effects Commonly Seen With Discontinuation Of GLP-1 Agonists With Nasal Anti-CD3
10/01/2025 13:15
Jan 10 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA ANNOUNCES REDUCTION OF SIDE EFFECTS COMMONLY SEEN
WITH
DISCONTINUATION OF GLP-1 AGONISTS WITH NASAL ANTI-CD3
* TIZIANA LIFE SCIENCES LTD - GLP-1 DRUGS FACE LONG TERM
TOLERABILITY ISSUES
* TIZIANA LIFE SCIENCES LTD - FDA ALLOWS ADDITIONAL 20
PATIENTS IN
FORALUMAB EXPANDED ACCESS PROGRAM
Source text: urn:newsml:reuters.com:*:nGNX1JJ8Xz
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsTiziana's experimental MS treatment meets main goals in mid-stage study
Brief: Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
Brief: Tiziana Announces Last Patient Completes Last Visit In Phase 2A Inform-MS Trial Of Intranasal Foralumab
Brief: Tiziana Announces Last Patient Successfully Dosed In Its Phase 2 Inform-MS Trial
Brief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis